Assessment of effectiveness of oral administration of collagen peptide on bone metabolism in growing and mature rats

Before any dietary supplement can be recommended for widespread daily use, someone needs to test what happens at very high doses. If a supplement is safe at ten times or one hundred times the recommended intake, that safety margin gives regulators and consumers confidence that a normal daily dose is nowhere near a danger threshold. For oral collagen peptides, this 2004 Japanese study filled that gap.

Researchers at Japan's National Institute of Health and Nutrition fed collagen peptides to two groups of rats. In the first experiment, growing male rats received either a dose equivalent to the recommended human daily amount, ten times that amount, or one hundred times that amount, every day for four weeks. In the second experiment, adult female rats were first put on a low-calcium diet for nine weeks to make them lose bone density, then treated with collagen peptides for eight weeks.

The results carry two important messages. First, in the growing rats, the top dose (one hundred times recommended) did increase bone density in the leg bones — but it also caused the kidneys to enlarge, a warning sign of kidney stress. Second, in the adult calcium-deficient females, ten times the recommended dose restored bone density in the thigh and lower spine to levels seen in normally-fed rats, with no obvious kidney or other adverse effects. This is the paper cited by Iwai 2005 and later collagen safety reviews to support the position that normal supplemental doses (up to roughly 15 g/day in humans) fall well within the safety margin, but that pushing much higher may risk kidney effects. Every safety discussion of oral collagen ultimately traces back to this study.